Citius Pharmaceuticals is expected to report a Q2 2026 consensus loss of $0.36 per share on revenue of approximately $12.52 million, while the stock currently trades at $0.68 against a much higher analyst price target of $5.00.
Investors are primarily focused on the commercial trajectory of LYMPHIR and its continued formulary adoption across major oncology treatment centers. Following the drug's December 2025 launch, the company has transitioned into a revenue-generating business, though shareholders are seeking proof of sustained demand after an initial channel-fill period.
Additionally, management’s guidance on the regulatory timeline for the Mino-Lok antibiotic lock solution and the company's overall cash runway remains critical for the stock's mid-term outlook.